Current Options for Systemic Therapy in Mesothelioma

Seminars in Thoracic and Cardiovascular Surgery

Volumn 21, Issue 2, 2009, Pages 154-158

  Jackman, David M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

chemotherapy; mesothelioma

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRS 207; DASATINIB; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; MESOTHELIN VACCINE; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY; MORAB 009; NAVELBINE; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RANPIRNASE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VATALANIB; VINBLASTINE; VORINOSTAT;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; FATIGUE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; SYSTEMIC THERAPY; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 70349731674     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2009.06.010     Document Type: Article

References (63)

1. Travis W.D., Brambilla E., Muller-Hermelink H.K., et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus, and Heart (2004), IARC, Lyon
2. Edwards J.G., Abrams K.R., Leverment J.N., et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55 (2000) 731-735
3. Herndon J.E., Green M.R., Chahinian A.P., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
4. van Klaveren R.J., Aerts J.G., de Bruin H., et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 43 (2004) 63-69
5. Byrne M.J., and Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 (2004) 257-260
6. Muers M.F., Stephens R.J., Fisher P., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 371 (2008) 1685-1694
7. Solheim O.P., Saeter G., Finnanger A.M., et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65 (1992) 956-960
8. Shih C., Chen V.J., Gossett L.S., et al. LY231514, a pyrrolo[2,3-Z]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57 (1997) 1116-1123
9. Taylor E.C., Kuhnt D., Shih C., et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-Z]pyrimidine-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35 (1992) 4450-4454
10. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
11. Santoro A., O'Brien M.E., Stahel R., et al. Pemetrexed plus cisplatin (P+ Cis) or pemetrexed plus carboplatin (P+ Cb) for chemonaive patients with malignant pleural mesothelioma (MPM): Results of the international expanded Access Program (EAP). J Clin Oncol 25 (2007) 7562
12. Taylor P., Castagneto B., Dark G., et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: Results of an international expanded access program. J Thorac Oncol 3 (2008) 764-771
13. Janne P.A., Wozniak A.J., Belani C.P., et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a phase IIIB expanded access program. J Thorac Oncol 1 (2006) 506-512
14. Jassem J., Ramlau R., Santoro A., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26 (2008) 1698-1704
15. van den Bogaert D.P., Pouw E.M., van Wijhe G., et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 1 (2006) 25-30
16. Bischoff H.G., Manegold C., Knopp M., et al. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17 (1998) A464 (abstract 1784)
17. Kindler H.L., Millard F., Herndon II J.E., et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31 (2001) 311-317
18. van Meerbeeck J.P., Baas P., Debruyne C., et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85 (1999) 2577-2582
19. Castagneto B., Zai S., Dongiovanni D., et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study. Am J Clin Oncol 28 (2005) 223-226
20. Kalmadi S.R., Rankin C., Kraut M.J., et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60 (2008) 259-263
21. Nowak A.K., Byrne M.J., Williamson R., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87 (2002) 491-496
22. Byrne M.J., Davidson J.A., Musk A.W., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II trial. J Clin Oncol 17 (1999) 25-30
23. van Haarst J.M., Baas P., Manegold C., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86 (2002) 342-345
24. Karrison T., Kindler H.L., Gandara D.R., et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma (MM). Proc Am Soc Clin Oncol 18 (2007) S391 (abstract 7526)
25. Ryad A.Y., Mostafa E., Salem D.A., et al. Assessment of survival and clinical benefit in malignant pleural mesothelioma (MPM) patients treated with gemcitabine and carboplatin. J Egypt Natl Cancer Inst 19 (2007) 61-70
26. Favaretto A.G., Aversa S.M., Paccagnella A., et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study. Cancer 97 (2003) 2791-2797
27. Lee C.W., Murray N., Anderson H., et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer 64 (2009) 308-313
28. Stebbing J., Powles T., McPherson K., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63 (2009) 94-97
29. Sorensen J.B., Frank H., and Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99 (2008) 44-50
30. Lerner HJ, Schoenfeld DA, Martin A, et al: Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52:1981-1985v
31. Sorensen P.G., Bach F., Bork E., et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69 (1985) 1431-1432
32. Magri M.D., Veronesi A., Foladore S., et al. Epirubicin in the treatment of malignant mesothelioma: A phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)-Mesothelioma Committee. Tumori 77 (1991) 49-51
33. Mattson K., Giaccone G., Kirkpatrick A., et al. Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10 (1992) 824-828
34. Konig J., Tolnay E., Wiethege T., et al. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 67 (2000) 36-40
35. Konig J.E., Tolnay E., Wiethege T., et al. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435 (1999) 8-12
36. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 (2001) 468-475
37. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
38. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
39. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666622676
40. Jahan T.M., Gu L., Wang X., et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol 24 suppl (2006) (abstract 7081)
41. Janne P.A., Wang E.F., Krug L.M., et al. Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol 25 suppl (2007) 3936 (abstract 7707)
42. Nowak A.K., Millward M.J., Francis R., et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 26 (2008) S439 (abstract 8063)
43. Dazzi H., Hasleton P.S., Thatcher N., et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61 (1990) 924-926
44. Govindan R., Suppiah R., and Ritter J. EGFR and Her-2 overexpression in malignant mesothelioma. Proc Am Soc Clin Oncol 20 (2001) 3106 (abstract)
45. Govindan R., Kratzke R.A., Herndon II J.E., et al. Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11 (2005) 2300-2304
46. Janne P.A., Taffaro M.L., Salgia R., et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62 (2002) 5242-5247
47. Garland L.L., Rankin C., Gandara D.R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study. J Clin Oncol 25 (2007) 2406-2413
48. Jackman D.M., Kindler H.L., Yeap B.Y., et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113 (2008) 808-814
49. Coffey D.C., Kutko M.C., Glick R.D., et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 35 (2000) 577-581
50. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
51. Richon V.M., Sandhoff T.W., Rifkind R.A., et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97 (2000) 10014-10019
52. Krug L.M., Curley T., Schwartz L., et al. Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7 (2006) 257-261
53. http://www.clinicaltrials.gov/ct2/show/NCT00128102?term=vorinostat+and+mesothelioma&rank=1. Accessed: May 9, 2009
54. Lee I., Kalota A., Gewirtz A.M., et al. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res 27 1A (2007) 299-307
55. Mikulski S.M., Costanzi J.J., Vogelzang N.J., et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20 (2002) 274-281
56. Vogelzang N.J., Taub R.N., Shin D., et al. Phase III randomized trial of Onconase (onc) vs doxorubicin (DOX) in patients with unresectable malignant mesothelioma (UMM): Analysis of survival. Proc Am Soc Clin Oncol 19 (2000) A577 (abstract 2274)
57. Press release, AlfaCell May 28, 2008
58. Chang K., and Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93 (1996) 136-140
59. Hassan R., Ebel W., Routhier E.L., et al. Preclinical evaluation of Morab-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7 (2007) 20
60. Quian L., Verschraegen C.F., Mendoza J., et al. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res (2009) (in press)
61. Hassan R., and Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 44 (2008) 46-53
62. Thomas A.M., Santarsiero L.M., Lutz E.R., et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200 (2004) 297-306
63. Tsao A.S., He D.D., Saigal B., et al. Activated Src inase is expressed in malignant pleural mesothelioma tumors; dasatainib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration. Proc Am Soc Clin Oncol (1998) (abstract 1784)